530233 logo

Auro Laboratories Limited Stock Price

BSE:530233 Community·₹1.8b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

530233 Share Price Performance

₹284.00
68.00 (31.48%)
₹284.00
68.00 (31.48%)
Price ₹284.00

530233 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Moderate risk with poor track record.

5 Risks
0 Rewards

Auro Laboratories Limited Key Details

₹284.5m

Revenue

₹92.3m

Cost of Revenue

₹192.2m

Gross Profit

₹159.8m

Other Expenses

₹32.4m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
5.20
67.56%
11.39%
100.8%
View Full Analysis

About 530233

Founded
1989
Employees
n/a
CEO
Sharat Deorah
WebsiteView website
www.aurolabs.com

Auro Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and generic formulations in India. It offers antihistamine; muscle relaxant; diuretic; iron deficiency; anti-diabetic, including Metformin HCL; anti-fungal, ulcer, malaria, and inflammatory; iodine supplement; analgesics; antacids; potassium and sodium iodide; and microcrystalline cellulose. The company also provides specialty chemicals comprising guanidine nitrate; dimethyl amine HCl; 2-ethoxy benzoic acid; and 3,4,5 - trimethoxy benzoic acid. In addition, it offers intermediates consisting of glibenclamde sulphonamide for use in API glibenclamide; cis-bramo benzoate and cls-tosylate that are used in API Ketoconazol; 3,4,5 - trimethoxy benzoic acid; 2-ethoxy benzoic acid for use in API sildenafil citrate; and 5-bromo phthalide that is used in API citalopram. It also exports products to Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain, and the United Kingdom. The company was incorporated in 1989 and is based in Mumbai, India.

Recent 530233 News & Updates

Recent updates

No updates